Literature DB >> 21055690

The use of immunohistochemistry in liver tumors.

Elaine S Chan1, Matthew M Yeh.   

Abstract

A variety of benign and malignant neoplasms can be encountered in the liver. Hematoxylin and eosin-stained tissue sections alone may not yield sufficient information to definitively diagnose liver tumors; therefore, ancillary studies with immunohistochemical markers can play a crucial role in differentiating the different hepatic neoplasms. The recent development of oncofetoprotein glypican-3 has added to the value of immunohistochemistry in diagnosing liver cancer. This review discusses the immunohistochemical markers used most often in the diagnosis of hepatic tumors.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Year:  2010        PMID： 21055690     DOI： 10.1016/j.cld.2010.10.001

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN： 1089-3261            Impact factor:   6.126


  11 in total

1.  Expression of VEGF and MMP-9 and MRI imaging changes in cerebral glioma.

Authors:  Yang Liu; Yang Zhou; Xiu-Shi Zhang; Bao-Zhong Shen
Journal:  Oncol Lett       Date:  2011-08-17       Impact factor: 2.967

Review 2.  Current concepts in the immunohistochemical evaluation of liver tumors.

Authors:  Anne K Koehne de Gonzalez; Marcela A Salomao; Stephen M Lagana
Journal:  World J Hepatol       Date:  2015-06-08

3.  Rare Gingival Metastasis by Hepatocellular Carcinoma.

Authors:  Li-Jun Xue; Xiao-Bei Mao; Jian Geng; Ya-Nan Chen; Qian Wang; Xiao-Yuan Chu
Journal:  Case Rep Med       Date:  2017-03-12

4.  Primary Liver Cancers-Part 1: Histopathology, Differential Diagnoses, and Risk Stratification.

Authors:  Kun Jiang; Sameer Al-Diffhala; Barbara A Centeno
Journal:  Cancer Control       Date:  2018 Jan-Mar       Impact factor: 3.302

5.  Genomic variants link to hepatitis C racial disparities.

Authors:  Matthew M Yeh; Sarag Boukhar; Benjamin Roberts; Nairanjana Dasgupta; Sayed S Daoud
Journal:  Oncotarget       Date:  2017-08-01

6.  Clinical significance of glypican-3-positive circulating tumor cells of hepatocellular carcinoma patients: A prospective study.

Authors:  Michinori Hamaoka; Tsuyoshi Kobayashi; Yuka Tanaka; Hiroaki Mashima; Hideki Ohdan
Journal:  PLoS One       Date:  2019-05-29       Impact factor: 3.240

Review 7.  Application of Immunohistochemistry in the Pathological Diagnosis of Liver Tumors.

Authors:  Yoshihisa Takahashi; Erdenetsogt Dungubat; Hiroyuki Kusano; Dariimaa Ganbat; Yasuhiko Tomita; Sarandelger Odgerel; Toshio Fukusato
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

8.  Role of FNA and Core Biopsy of Primary and Metastatic Liver Disease.

Authors:  John P McGahan; John Bishop; John Webb; Lydia Howell; Natalie Torok; Ramit Lamba; Michael T Corwin
Journal:  Int J Hepatol       Date:  2013-11-21

9.  Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma.

Authors:  Ahmed Omar Kaseb; Manal Hassan; Sahin Lacin; Reham Abdel-Wahab; Hesham M Amin; Ahmed Shalaby; Robert A Wolff; James Yao; Asif Rashid; Bharathi Vennapusa; Janine Feng; Toshihiko Ohtomo
Journal:  Oncotarget       Date:  2016-10-25

Review 10.  Mitogen-Activated Protein Kinases (MAPKs) and Cholangiocarcinoma: The Missing Link.

Authors:  Chaobo Chen; Leonard J Nelson; Matías A Ávila; Francisco Javier Cubero
Journal:  Cells       Date:  2019-09-28       Impact factor: 6.600
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.